Eli Lilly now expects to report revenue of around $45bn in its forthcoming 2024 results. That’s some 32% ahead of the prior year, but about 3% lower than the reduced guidance issued in October.
The miss was driven by lower than expected fourth quarter growth in the market for hormone-based diabetes and obesity treatments, that include Lilly’s Mounjaro and Zepound.
In 2025, revenue is expected to land between $58-$61bn, growth of 32% at the midpoint, a little better than analysts had been forecasting.
The shares closed down 6.6% on the day.
Our view
HL view to follow.
Eli Lilly key facts
All ratios are sourced from Refinitiv, based on previous day’s closing values. Please remember yields are variable and not a reliable indicator of future income. Keep in mind key figures shouldn’t be looked at on their own – it’s important to understand the big picture.
This article is not advice or a recommendation to buy, sell or hold any investment.No view is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment.This article has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is considered a marketing communication.Non - independent research is not subject to FCA rules prohibiting dealing ahead of research, however HL has put controls in place(including dealing restrictions, physical and information barriers) to manage potential conflicts of interest presented by such dealing.Please see our full non - independent research disclosure for more information.